Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia.
暂无分享,去创建一个
R. Galanello | A. Piga | A. Cohen | A. Dhillon | I. Wanless | E. Schwartz | M. Guido | G. Sweeney | M. Gamberini
[1] P. O'Brien,et al. Iron complexes of deferiprone and dietary plant catechols as cytoprotective superoxide radical scavengers(1). , 2001, Biochemical pharmacology.
[2] M. Sherman,et al. The Laennec grading system for assessment of hepatic fibrosis Validation by correlation with wedged hepatic vein pressure and clinical features , 2000 .
[3] R. Lindeman,et al. The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1). , 2000, Transfusion science.
[4] Matthew Darlison,et al. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register , 2000, The Lancet.
[5] Vullo,et al. Safety profile of the oral iron chelator deferiprone: a multicentre study , 2000, British journal of haematology.
[6] J. Balfour,et al. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases. , 1999, Drugs.
[7] Aydinok,et al. ALTERNATE USE OF DEFERIPRONE AND DESFERRIOXAMINE IN PRIMARY SCHOOL CHILDREN WITH THALASSAEMIA MAJOR , 1999, British journal of haematology.
[8] T. Einarson,et al. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1) , 1999, European Journal of Clinical Pharmacology.
[9] A. Maggio,et al. Iron chelation with oral deferiprone in patients with thalassemia. , 1998, The New England journal of medicine.
[10] D. Weatherall,et al. Iron chelation with oral deferiprone in patients with thalassemia. , 1998, New England Journal of Medicine.
[11] R. Grady,et al. Iron chelation with oral deferiprone in patients with thalassemia. , 1998, New England Journal of Medicine.
[12] M. Spino,et al. Iron chelation with oral deferiprone in patients with thalassemia. , 1998, The New England journal of medicine.
[13] Wright,et al. Combined therapy with deferiprone and desferrioxamine , 1998, British journal of haematology.
[14] K. Fleming,et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. , 1998, The New England journal of medicine.
[15] M. Kaplan,et al. Iron-chelation therapy with oral deferiprone--toxicity or lack of efficacy? , 1998, The New England journal of medicine.
[16] A. Hirt,et al. Liver iron and fibrosis during long‐term treatment with deferiprone in Swiss thalassaemic patients , 1998, British journal of haematology.
[17] P. Bedossa,et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.
[18] K. Ishak,et al. Histological grading and staging of chronic hepatitis. , 1995 .
[19] P. Bedossa,et al. Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients with Chronic Hepatitis C , 1994 .
[20] J. Lloyd-Still,et al. A prospective evaluation of iron chelation therapy in children with severe beta-thalassemia. A six-year study. , 1988, American journal of diseases of children.
[21] A. Hoffbrand,et al. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. , 1987, British medical journal.
[22] A. Hoffbrand,et al. Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine. , 1987, Journal of clinical pathology.
[23] G. Kontoghiorghes. NEW ORALLY ACTIVE IRON CHELATORS , 1985, The Lancet.
[24] A. Hoffbrand,et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. , 1998, Blood.
[25] A. Piga,et al. Results of long-term iron-chelating therapy. , 1996, Acta haematologica.
[26] J. H. Zar,et al. Biostatistical Analysis (5th Edition) , 1984 .
[27] Bernice W. Polemis. Nonparametric Statistics for the Behavioral Sciences , 1959 .